Subgroup analyses showed that PFS was significantly improved in patients with HR-negative cancers, but not with HR+ cancers, suggesting that ER+ breast cancers may be biologically different, and ER may act as an escape pathway when HER2 but not ER is inhibited. This evidence concerns the gene ERBB2 and breast carcinoma.